Imprime PGG (Colorectal Cancer) - Forecast and Market Analysis to 2023


Naperville, IL -- (SBWIRE) -- 12/31/2014 -- Reportstack, provider of premium market research reports announces the addition of Imprime PGG (Colorectal Cancer) - Forecast and Market Analysis to 2023 market report to its offering

Imprime PGG (Colorectal Cancer) - Forecast and Market Analysis to 2023


The publisher has released its new PharmaPoint Drug Evaluation report, Imprime PGG (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Biotheras Imprime PGG is an immunotherapy in Phase III development in the US and Europe for the treatment of chemotherapy-refractory KRAS wild-type metastatic CRC in combination with the EGFR inhibitor Erbitux. Its open-label pivotal study has an estimated enrollment of 795 patients, and these patients will be randomized (2:1) to either Imprime PGG and Erbitux or Erbitux alone. The trial has a primary endpoint of OS, with final data for this outcome expected in April 2016; the company is investigating the potential to apply for accelerated approval based on interim data when available.


- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Imprime PGG including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Imprime PGG for the top six countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Imprime PGG performance

- Obtain sales forecast for Imprime PGG from 2013-2023 in top six countries (the US, France, Germany, Italy, Spain and the UK)

Complete report is available

Roger Campbell
United States
Ph: 888-789-6604